Study: Psilocybin Better Than SSRIs in Treating Depression
Psilocybin, the active compound in magic mushrooms, may soon be a new option for treating depression. A recent clinical trial found that psilocybin is at least as effective as one of the most commonly prescribed antidepressants, escitalopram (Lexapro). But what sets psilocybin apart?
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
Comparing Psilocybin to SSRIs and Traditional Antidepressants
Researchers published their findings on September 21 in The Lancet’s eClinicalMedicine and presented them at the European College of Neuropsychopharmacology’s annual meeting. The study found that patients with severe depression who took either a single dose of psilocybin or a six-week course of escitalopram showed similar improvements in their symptoms. According to lead researcher Tommaso Barba, “Both treatments led to comparable improvements in alleviating symptoms of depression at the six-week mark, such as sadness and negative emotions.”
But psilocybin did more than alleviate depression. Barba noted, “Psilocybin outperformed escitalopram in several measures of well-being, meaning in life, work and social functioning.” Patients reported long-term benefits, including a deeper sense of meaning and better psychological connectedness to others. These results continued for six months after treatment.
A Holistic Approach to Mental Health
SSRIs, such as Prozac and Zoloft, have long been the standard for treating depression. However, they don’t work for everyone, with about a third of patients failing to respond to treatment. Barba explained, “SSRIs work well, but not for everyone. They are also associated with some side effects.” In contrast, psilocybin might provide a “real alternative, and perhaps additional benefits, to people who are worried about taking conventional antidepressants.”
The trial involved 59 patients with severe depression, with 30 undergoing psilocybin therapy and 29 taking escitalopram for six weeks. Six months later, both groups reported similar improvements in their depressive symptoms. However, only psilocybin improved patients’ overall sense of well-being and their ability to find meaning in life.
RELATED: Researches Gave Autistic Dogs LSD and It Made Them More Connected
Could Psilocybin Revolutionize Depression Treatment?
According to Dr. David Erritzoe, clinical director of the Center for Psychedelic Research at Imperial College London, “Improving connectedness and having greater meaning in life can significantly enhance a person’s quality of life and long-term mental health.” He added that psilocybin therapy might offer a more holistic approach, addressing both depressive symptoms and well-being.
However, Erritzoe emphasized that psilocybin is still experimental and should only be administered in controlled settings. “These precautions are not found in recreational psychedelic use,” Erritzoe cautioned. For now, psilocybin represents a potential breakthrough, but more research and careful oversight are needed before it becomes widely available.
